Targeting Tau Seed Propagation Following Anti-Amyloid Clearance: Emerging Combination Clinical Trials
Study Design & Technical Specifications
Sample Size / Cohort
Documented in primary study
Subject / Study Model
CNS Experimental / Clinical Model
Analytical Modalities
Executive Research Summary
AI SummaryPrimary Abstract & Repository Description
Source: AlzforumEditorial Critique, Methodological Value & Reusability Guide
1. Scientific Context & Premise
Primary Premise (Alzforum): "Review of next-generation trial designs combining anti-amyloid monoclonal antibodies with microtubule-binding region (MTBR-tau) targeted antibodies to halt secondary neurodegeneration." Within Alzheimer's Disease (AD), this work examines Tau, Combination Therapy, Clinical Trials, Lecanemab, MTBR-tau in relation to Aβ42/40, p-tau217, p-tau181, GFAP, NfL, and APOE ε4 genotype interactions. Authored by Alzforum Conference Reporting Team.
2. Study Architecture & Findings
Study Architecture: Experimental / Clinical CNS Design (primary study cohort) utilizing Tau PET, Clinical Endpoints. Key reported conclusion: "Review of next-generation trial designs combining anti-amyloid monoclonal antibodies with microtubule-binding region (MTBR-tau) targeted antibodies to halt secondary neurodegeneration."
3. Secondary Analysis & Reusability
Secondary Analysis Applications: (1) Cross-referencing Tau PET, Clinical Endpoints variables (Tau, Combination Therapy, Clinical Trials, Lecanemab, MTBR-tau) against open repositories in Alzheimer's Disease (AD); (2) Benchmarking feature distributions and effect sizes reported in "Targeting Tau Seed Propagation Following Anti-Amyloid Clearance: Emerging Combin"; (3) Informing cohort stratification and endpoint selection.
4. Methodological Caveats & Governance
Methodological Note: When integrating these Tau PET, Clinical Endpoints findings, account for cohort-specific inclusion criteria (primary study cohort), potential site/instrument batch effects, and repository license terms (open_access).
Data Access, Reproducibility & Analysis Starter Guide
BIDS (Brain Imaging Data Structure) v1.9+
Quick Data Access & Structured Export
Open the primary repository directly or download structured metadata (JSON / CSV) in one click.
This neuroimaging resource follows the Brain Imaging Data Structure (BIDS) specification, organizing raw NIfTI volumes (.nii.gz), acquisition parameters (.json sidecars), and participant phenotype tables (participants.tsv) in a deterministic directory hierarchy.
Tags & Modalities
Bibliometrics, Peer-Review Status & Citation Export
Cross-referenced via Semantic Scholar, Europe PMC & bioRxiv
1. Citation Metrics & Context Breakdown
Citation Context Breakdown
2. Peer-Review Validation & Revision History
Verified Publication / Open Dataset Record
Metadata and license integrity verified against primary repository records.
3. Standardized Academic Citation & BibTeX Export
Alzforum Conference Reporting Team (2026). Targeting Tau Seed Propagation Following Anti-Amyloid Clearance: Emerging Combination Clinical Trials. Alzforum. https://www.alzforum.org/news/conference-coverage/tau-therapeutics-next-frontier
@article{team2026alzf,
title = {Targeting Tau Seed Propagation Following Anti-Amyloid Clearance: Emerging Combination Clinical Trials},
author = {Alzforum Conference Reporting Team},
year = {2026},
journal = {Alzforum},
howpublished = {\url{https://www.alzforum.org/news/conference-coverage/tau-therapeutics-next-frontier}},
doi = {},
note = {CNS Open Data: alzheimer}
}Related Alzheimer's & Dementia Research & Datasets
Explore All DatasetsAgora Target Validation: INPP5D (inositol polyphosphate-5-phosphatase D) in Alzheimer’s Disease
This gene is a member of the inositol polyphosphate-5-phosphatase (INPP5) family and encodes a protein with an N-terminal SH2 domain, an inositol phosphatase domain, and two C-terminal protein interaction domains. Expression of this protein is restricted to hematopoietic cells where its movement from the cytosol to the...
Agora Target Validation: NRN1 (neuritin 1) in Alzheimer’s Disease
This gene encodes a member of the neuritin family, and is expressed in postmitotic-differentiating neurons of the developmental nervous system and neuronal structures associated with plasticity in the adult. The expression of this gene can be induced by neural activity and neurotrophins. The encoded protein contains a ...
Agora Target Validation: BIN1 (bridging integrator 1) in Alzheimer’s Disease
This gene encodes several isoforms of a nucleocytoplasmic adaptor protein, one of which was initially identified as a MYC-interacting protein with features of a tumor suppressor. Isoforms that are expressed in the central nervous system may be involved in synaptic vesicle endocytosis and may interact with dynamin, syna...
Agora Target Validation: HTRA1 (HtrA serine peptidase 1) in Alzheimer’s Disease
This gene encodes a member of the trypsin family of serine proteases. This protein is a secreted enzyme that is proposed to regulate the availability of insulin-like growth factors (IGFs) by cleaving IGF-binding proteins. It has also been suggested to be a regulator of cell growth. Variations in the promoter region of ...
Agora Target Validation: APOE (apolipoprotein E) in Alzheimer’s Disease
The protein encoded by this gene is a major apoprotein of the chylomicron. It binds to a specific liver and peripheral cell receptor, and is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. This gene maps to chromosome 19 in a cluster with the related apolipoprotein C1 and C2 genes. Mu...
Allen Brain Atlas: Multi-plane optical physiology during image change detection
Time series of behavioral variables and neural activity measured with multi-plane in vivo 2-photon imaging in mice performing a visual change detection task where mice were trained with image set A and tested with a novel image set B... Freely accessible open data product maintained by the Allen Institute for Brain Science.
Active Clinical Trials & Pipeline in Alzheimer's & Dementia
View Clinical PipelineRelated Data & Resources
Academic Research & Medical Information Disclaimer
This page provides structured scientific metadata, methodological critiques, and open-data reusability guidelines intended strictly for neuroscience researchers and data scientists. It does not constitute medical advice, clinical diagnosis, or treatment recommendations.
Was this resource helpful?
Help improve data curation by sharing your feedback.